Invention Grant
- Patent Title: JAK1 selective inhibitors and uses thereof
-
Application No.: US16333994Application Date: 2017-09-30
-
Publication No.: US10738060B2Publication Date: 2020-08-11
- Inventor: Congxin Liang
- Applicant: TLL Pharmaceutical, LLC
- Applicant Address: US NJ Iselin
- Assignee: TLL Pharmaceutical, LLC
- Current Assignee: TLL Pharmaceutical, LLC
- Current Assignee Address: US NJ Iselin
- Agency: Sheppard Mullin Richter & Hampton LLP
- International Application: PCT/US2017/054668 WO 20170930
- International Announcement: WO2018/067422 WO 20180412
- Main IPC: C07D491/12
- IPC: C07D491/12 ; A61K31/437 ; C07D491/147 ; A61P19/02 ; C07D211/00
Abstract:
The new 1H-furo[3,2-b]imidazo[4,5-d]pyridine derivatives are selective Jak1 kinase inhibitors useful in treating disorders related to Jak1 activities such as autoimmune diseases or disorders, inflammatory diseases or disorders, and cancer or neoplastic diseases or disorders.
Public/Granted literature
- US20190256523A1 NOVEL JAK1 SELECTIVE INHIBITORS AND USES THEREOF Public/Granted day:2019-08-22
Information query
